1990504-34-1
Chemical Structure
Bomedemstat
Synonym(s): IMG-7289
- CAS No.: 1990504-34-1
- Formula:C28H34FN7O2
- Molecular Weight:519.61
IUPAC Name: N-((S)-5-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl)-4-(1H-1,2,3-triazol-1-yl)benzamide
InChIKey: KQKBMHGOHXOHTD-KKUQBAQOSA-N
SMILES: O=C(N1CCN(CC1)C)[C@@H](NC(C2=CC=C(N3C=CN=N3)C=C2)=O)CCCN[C@H]4[C@@](C5=CC=C(C=C5)F)([H])C4
Biological Activity: Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bomedemstat | 99.43% | Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.74
HY-109169ABomedemstat ditosylate -
Similarity Score 0.53
HY-183202NCD38 -
Similarity Score 0.51
HY-112304NCD38 TFA -
Similarity Score 0.51
HY-112304A(1R,2S)-NCD38 TFA -
Similarity Score 0.50
HY-123915Antimalarial agent 20 -
Similarity Score 0.50
HY-160822AGG-523 -
Similarity Score 0.49
HY-149978LSD1-IN-26 -
Similarity Score 0.49
HY-10269LY-517717 -
Similarity Score 0.47
HY-111348Lamifiban -
Explore the MedChemAI to find more analogs
References
- [1]. Jonas S Jutzi,et al. LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere.2018 Jun 8;2(3):e54. [Content Brief]
- [2]. Yuan Fang, et al. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019 Dec 4;12(1):129. [Content Brief]
